Keros Therapeutics, Inc. (KROS) - Form 8-K Summary
Business Context and Reporting Period
Keros Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 3, 2026. The filing announces the financial results for the quarter ended June 30, 2026. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol "KROS."
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K serves as a notification that results were announced via a press release (Exhibit 99.1), but the numerical data is not embedded in the provided text.
Material Changes
The filing text does not contain specific details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended June 30, 2026, by reviewing Exhibit 99.1 (Press Release) as the numbers are not present in the 8-K text.
- Confirm the company's cash position and runway, as this is critical for a clinical-stage biopharmaceutical company, though not detailed in this summary text.
- Note that the financial information in this filing is furnished and not incorporated by reference into other Securities Act filings unless expressly stated.